Regeneron Pharmaceuticals, Inc.
REGN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $14,202,000 | $13,117,200 | $12,172,900 | $16,071,700 |
| % Growth | 8.3% | 7.8% | -24.3% | – |
| Cost of Goods Sold | $1,970,500 | $2,244,500 | $1,705,200 | $2,723,700 |
| Gross Profit | $12,231,500 | $10,872,700 | $10,467,700 | $13,348,000 |
| % Margin | 86.1% | 82.9% | 86% | 83.1% |
| R&D Expenses | $5,233,000 | $3,986,700 | $3,056,100 | $2,621,900 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2,954,400 | $2,539,500 | $2,115,900 | $1,824,900 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $53,400 | -$2,100 | -$89,900 | -$45,600 |
| Operating Expenses | $8,240,800 | $6,524,100 | $5,082,100 | $4,401,200 |
| Operating Income | $3,990,700 | $4,348,600 | $5,385,600 | $8,946,800 |
| % Margin | 28.1% | 33.2% | 44.2% | 55.7% |
| Other Income/Exp. Net | $789,200 | -$149,300 | -$526,800 | $379,000 |
| Pre-Tax Income | $4,779,900 | $4,199,300 | $4,858,800 | $9,325,800 |
| Tax Expense | $367,300 | $245,700 | $520,400 | $1,250,500 |
| Net Income | $4,412,600 | $3,953,600 | $4,338,400 | $8,075,300 |
| % Margin | 31.1% | 30.1% | 35.6% | 50.2% |
| EPS | 40.9 | 37.05 | 40.51 | 76.4 |
| % Growth | 10.4% | -8.5% | -47% | – |
| EPS Diluted | 38.34 | 34.77 | 38.22 | 71.97 |
| Weighted Avg Shares Out | 107,900 | 106,700 | 107,100 | 105,700 |
| Weighted Avg Shares Out Dil | 115,100 | 113,700 | 113,500 | 112,200 |
| Supplemental Information | – | – | – | – |
| Interest Income | $711,400 | $495,900 | $160,100 | $0 |
| Interest Expense | $55,200 | $73,000 | $59,400 | $57,300 |
| Depreciation & Amortization | $482,900 | $421,000 | $341,400 | $286,200 |
| EBITDA | $5,318,000 | $4,693,300 | $5,259,600 | $9,669,300 |
| % Margin | 37.4% | 35.8% | 43.2% | 60.2% |